Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dan-Cristian Popescu has a total of 6 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    An Exploratory Narrative Review of Environmental, Socioeconomic, and Occupational Determinants of Cardiovascular Risk

    by Alexandru-Cristian Nechita, Dan-Cristian Popescu, Mara Diaconu, Bogdan Marcu, Vasilica Enache

    Cardiovascular disease (CVD) is the most important contributor to global mortality and disability, and its aetiology extends well beyond the classical behavioural and metabolic risk factors. This exploratory narrative review examines selected international evidence on air and water pollution, geological and urban exposures, socioeconomic disadvantage, and working conditions in mining, metallurgy, automotive manufacturing, agriculture and sedentary or psychosocially demanding occupations. Central and Eastern Europe, including Romania, is considered as a contextual example rather than a separately studied population. We also sought to describe the mechanisms through which specific risk factors trigger harmful pathophysiological responses. Associations differ by exposure definition, outcome, study design and source population. The review identifies prevention and research priorities while acknowledging its purposive evidence selection, heterogeneous populations and lack of a systematic search or new pooled analysis. Population-specific longitudinal and intervention studies are needed to quantify joint effects and the cardiovascular benefits of structural prevention.

  • Open Access

    Association of Baseline and Serial High-Sensitivity Cardiac Troponin T with In-Hospital Mortality Across Clinical Presentation, LVEF and Diabetes Status in Decompensated Heart Failure

    by Mara Diaconu, Dan-Cristian Popescu, Diana Țînț, Alexandru-Cristian Nechita

    Background/Objectives: High-sensitivity cardiac troponin T (hs-cTnT) is frequently elevated in decompensated heart failure (DHF), but its prognostic association may vary according to clinical context. We evaluated baseline and serial hs-cTnT in relation to in-hospital mortality across clinical presentation, left ventricular ejection fraction (LVEF) and diabetes status. Methods: A total of 653 patients hospitalized with DHF were prospectively analyzed. Baseline hs-cTnT was assessed globally and across clinical presentation, LVEF and diabetes status. Among 334 patients with repeated measurements, serial hs-cTnT was evaluated using continuous measures and threshold-based trajectories. Results: In-hospital mortality was 9.0%. Baseline hs-cTnT showed moderate discrimination for mortality (AUC 0.658). The internally derived 38.4 pg/mL threshold identified higher mortality above versus below the threshold (14.8% vs. 5.1%, p < 0.001) but showed limited bootstrap stability. Clinical presentation significantly modified the association between hs-cTnT and mortality (global interaction p = 0.022), driven by a stronger association in decompensated right-sided versus left-sided HF (ratio of ORs 2.77, 95% CI 1.26–6.07). No significant modification effect was observed by LVEF or diabetes status. In a serial subgroup, repeated hs-cTnT remained associated with mortality after multivariable adjustment (OR 1.59 per doubling, 95% CI 1.14–2.21), although the increase in discrimination over the baseline model was not significant (AUC 0.750 vs. 0.777, p = 0.205). The above-above trajectory remained associated with mortality in Firth regression (adjusted OR 2.32, 95% CI 1.02–5.61). Conclusions: hs-cTnT was associated with in-hospital mortality in DHF, with heterogeneity by clinical presentation. Serial measurements were associated with outcome, but their incremental discrimination value was limited. Threshold-based trajectories should be considered exploratory pending external validation.

  • Open Access

    Accelerated Atherosclerosis

    by Alexandru-Cristian Nechita, Dan-Cristian Popescu, Mara Diaconu, Adrian-Claudiu Popa, Bogdan Marcu, Vasilica Enache

    Accelerated atherosclerosis (AA) denotes a disproportionately early and rapid progression of arterial atheroma unpredictable by standard tools. Clinicians often rely on simplified frameworks for cardiovascular risk assessment, which may overlook genetic and pathological conditions associated with AA. Some of these are well established, others are considered future therapy targets. This review examines the conditions in which AA is most firmly established, including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), antiphospholipid syndrome, chronic kidney disease (CKD), human immunodeficiency virus (HIV), diabetes mellitus, and psoriasis. We also examined the importance of genetic determinants of AA, with particular emphasis on clonal hematopoiesis of indeterminate potential (CHIP) and lipoprotein (a) (Lp(a)); contemporary imaging-based detection and monitoring; the diagnostic role of circulating non-coding microRNAs; and complementary protein biomarkers of residual inflammatory risk. After identifying biomarkers of increased cardiovascular risk and possible AA, clinicians should assess atherosclerotic disease directly using the available imaging techniques, most of which are non-invasive. The clinical consequences of AA are discussed and a comprehensive review of the therapeutic options is provided to offer a practical approach.

  • Open Access

    Cardiovascular–Kidney–Metabolic Syndrome and Its Hepatic Dimension: A Narrative Review

    by Vasilica Enache, Dan-Cristian Popescu, Bogdan Marcu, Mara Diaconu, Alexandru-Cristian Nechita

    Metabolic syndrome came to the attention of the scientific community several decades ago, and its definition has undergone multiple changes over time. It is currently defined by the coexistence of hypertension, central obesity, dyslipidemia, and impaired glucose metabolism, with insulin resistance, chronic inflammation, and oxidative stress representing important underlying pathophysiological mechanisms. The latter two processes are major promoters of the onset and progression of atherosclerosis. In parallel, many individuals develop metabolic dysfunction-associated steatotic liver disease (MASLD), formerly called non-alcoholic fatty liver disease (NAFLD). Growing evidence indicates that MASLD may interact bidirectionally with cardiovascular, renal, and metabolic dysfunction and may contribute to cardiometabolic risk. These observations have prompted proposals for a broader cardio–reno–hepato–metabolic axis. However, MASLD is not currently included in the established cardiovascular-kidney-metabolic (CKM) definition or staging system, and its incorporation remains an evolving conceptual extension. Prediabetes is a reversible condition characterized by abnormal glucose levels that do not meet the diagnostic criteria for diabetes. The American Diabetes Association defines prediabetes as glycated hemoglobin (HbA1c) = 5.7–6.4%, fasting plasma glucose = 100–125 mg/dL, or two-hour plasma glucose during an oral glucose tolerance test = 140–199 mg/dL. This comprehensive review examines traditional and genetic risk determinants, shared pathophysiological mechanisms, diagnostic strategies, clinical manifestations, emerging phenotypes, circulating microRNAs as non-invasive biomarkers, complications, and the principal therapeutic strategies, including diet, exercise, and pharmacotherapy. Particular attention is given to the recent approvals of resmetirom and semaglutide for metabolic dysfunction-associated steatohepatitis and to the expanding roles of sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists and non-steroidal mineralocorticoid receptor antagonists. Cardiovascular, renal, metabolic, and hepatic disorders are frequently present in the same patient. Other individuals may develop this high-risk cluster over time. The aim of this article is to define the interplay between different metabolic conditions and to outline the best approach to diagnosis, monitoring, and effective integrated therapy.

  • Open Access

    Congestion–Perfusion Phenotypes and In-Hospital Mortality in Acute Heart Failure: Phenotype-Specific Prognostic Markers and Right-Heart Involvement

    by Mara Diaconu, Dan-Cristian Popescu, Diana Țînț, Alexandru-Cristian Nechita

    Background and Objectives: Acute heart failure (AHF) has heterogeneous clinical profiles and considerable short-term mortality. Bedside evaluation of congestion and peripheral perfusion may help identify clinically relevant risk groups. This study aimed to evaluate the relationship between a non-invasive congestion–perfusion classification and in-hospital mortality in patients hospitalized with AHF and to explore the prognostic relevance of clinical, biological, and right-heart variables within the phenotypes. Materials and Methods: We performed an observational study that analyzed 790 patients hospitalized with AHF. Patients were classified at presentation into four predefined congestion–perfusion phenotypes: non-congested/preserved perfusion, congested/preserved perfusion, non-congested/impaired perfusion, and congested/impaired perfusion. Congestion was defined using pulmonary and systemic markers, whereas impaired perfusion was defined by the presence of at least two predefined criteria of hypoperfusion. Clinical, biological, and echocardiographic parameters were analyzed according to phenotype and in-hospital mortality. Discriminative performance was evaluated using ROC curve analysis, and logistic regression models were constructed within the congestive phenotypes to investigate the prognostic value of combined clinical and biological markers, with bootstrap internal validation in the combined models. Results: 78 patients died during hospitalization, with different rates across phenotypes; 2.9% in non-congested/preserved perfusion, 3.0% in non-congested/impaired perfusion, 8.0% in congested/preserved perfusion, and 19.5% in congested/impaired perfusion. In congestive phenotypes, several adverse markers were identified. Exploratory combined models demonstrated discriminatory performance in the congested/preserved perfusion phenotype (AUC 0.731) and in the congested/impaired perfusion phenotype (AUC 0.838); bootstrap optimism-corrected AUCs were 0.693 and 0.785, respectively. Right ventricular parameters were more strongly associated with mortality in the congested/impaired perfusion phenotype. LVEF showed limited discrimination within individual phenotypes. Conclusions: The highest in-hospital mortality was observed in the congestive/impaired perfusion phenotype, with a more adverse clinical, biological, and echocardiographic profile. Within the congestive phenotypes, exploratory prognostic marker patterns were partially overlapping, while LVEF showed limited discrimination.


  • Open Access

    Occupational Stress as a Modifiable Risk Factor for Atherosclerotic Coronary Artery Disease: Evidence, Mechanisms, and Interventions

    by Dan-Cristian Popescu, Mara Ciobanu, Alexandru-Cristian Nechita

    Cardiovascular diseases, particularly atherosclerotic coronary artery disease (CAD), remain among the leading causes of mortality worldwide. Although traditional risk factors—such as arterial hypertension, dyslipidemia, diabetes mellitus, obesity, smoking, and physical inactivity—are well established, accumulating evidence highlights the significant role of psychosocial factors in modulating cardiovascular risk. Among these, occupational stress—conceptualized through models such as job strain (high job demands combined with low control) and effort–reward imbalance—has been consistently associated with an increased risk of coronary events. The interaction between occupational stress and classical cardiovascular risk factors remains insufficiently elucidated and challenging to quantify. This review examines the current scientific evidence regarding the relationship between occupational stress and CAD, synthesizing findings from major epidemiological studies and relevant meta-analyses. Chronic exposure to work-related stress activates neuroendocrine pathways, including the hypothalamic–pituitary–adrenal axis and the sympathetic nervous system, promotes a state of low-grade systemic inflammation, and facilitates the adoption of unhealthy behaviors such as smoking, poor dietary habits, physical inactivity, and excessive alcohol consumption. These mechanisms contribute to endothelial dysfunction, hypercoagulability, and acceleration of the atherosclerotic process. Landmark investigations, including the INTERHEART study, meta-analyses conducted by Kivimäki and colleagues, and prospective studies by Chandola on the metabolic syndrome, support both the cumulative and independent impact of occupational stress on cardiovascular risk. Although the proportion of risk attributable to occupational stress is lower than that associated with traditional risk factors, its modifiable nature underscores a substantial potential for targeted preventive interventions. Strategies aimed at reducing occupational stress encompass individual-level approaches (stress management programs, lifestyle modification, psychological support), organizational interventions (optimizing the balance between job demands and employee control, enhancing social support in the workplace), and public health policies (occupational health promotion programs, regulatory measures addressing work-related stress, and screening for occupational stress). Recognizing occupational stress as a modifiable risk factor for CAD has important implications for both clinical practice and public health. Future research should focus on large-scale longitudinal studies, the identification of stress-related biomarkers, and the cost-effectiveness of stress-reduction interventions in the prevention and management of coronary artery disease.

  • Open Access

    Echocardiographic Predictors of Clinical Outcomes in Cardiogenic Pulmonary Edema: Insights Into Ventricular Function and Intensive Care Requirements

    by Dan-Cristian Popescu, Ciobanu Mara, Diana Țînț, Alexandru-Cristian Nechita

    Background: Cardiogenic pulmonary edema (CPE) is a severe manifestation of acute heart failure (AHF), typically driven by elevated left ventricular (LV) filling pressures. While LV dysfunction has been the traditional focus, growing evidence highlights the role of right ventricular (RV) impairment and biventricular interaction in the pathophysiology and prognosis of AHF. Objectives: To characterize the clinical and echocardiographic profile of patients presenting with CPE and to assess the comparative prognostic contribution of LV and RV function to in-hospital outcomes. Methods: We retrospectively analyzed 28 patients with CPE from a larger AHF registry, excluding those with incomplete echocardiographic data or missing NT-proBNP measurement. Comprehensive echocardiographic assessment at admission included TAPSE, S RV, RV–RA gradient, LVEF, LVOT VTI, S LV, and E/E′ ratio. Clinical variables, NT-proBNP levels, and in-hospital outcomes (mortality, ventilation, inotropic support, ICU stay) were recorded. Group comparisons, correlation analyses, and ROC curve assessments were performed.Results: The mean S LV was significantly lower than S RV (7.34 ± 2.38 cm/s vs. 11.49 ± 2.70 cm/s; p < 0.001), indicating predominant LV longitudinal systolic impairment. Four patients (14.3%) died during hospitalization. No echocardiographic parameter reached statistical significance for predicting mortality. Patients with higher mitral E velocity and reduced LV systolic velocities tended to have longer ICU hospitalization.Trends toward lower S RV and higher S LV/S RV ratio were noted in patients requiring inotropes.Conclusions: In CPE, LV longitudinal systolic function is more impaired than RV function at presentation. While single echocardiographic indices lacked strong prognostic discrimination in this small cohort, integrated assessment of LV and RV systolic performance alongside diastolic filling pressures may improve early risk stratification. These findings align with the conceptual framework of composite prognostic tools and warrant validation in larger prospective studies.

  • Open Access

    The VIRTUE Index: A Novel Echocardiographic Marker Integrating Right–Left Ventricular Hemodynamics in Acute Heart Failure

    by Dan-Cristian Popescu, Mara Ciobanu, Diana Țînț, Alexandru-Cristian Nechita

    Background/Objectives: Acute heart failure (AHF) is a heterogeneous syndrome with phenotype-dependent prognosis. NT-proBNP is the reference biomarker, but standard echocardiographic measures (TAPSE, RV–RA gradient, LVOT VTI) offer only partial prognostic insight. The Virtue Index, defined as (RV–RA gradient)/(TAPSE × LVOT VTI), was introduced to integrate right–left ventricular interaction. This study evaluated its clinical and prognostic performance in AHF and its behavior across ejection-fraction phenotypes. Methods: We retrospectively analyzed 222 patients with AHF; complete data for Virtue calculation were available in 168 (99 HFrEF, 69 HFpEF) patients. HFmrEF patients were excluded from subgroup prognostic analyses. Correlation with NT-proBNP was assessed using Spearman testing with bootstrap intervals, and in-hospital mortality prediction was evaluated using ROC analysis with DeLong comparisons. Results: In HFpEF, the Virtue Index correlated moderately with NT-proBNP (ρ = 0.38, p = 0.002) and showed fair prognostic discrimination (AUC 0.704), similar to the RV–RA gradient (0.724) and higher than TAPSE or LVOT VTI. In HFrEF, correlation was weak (ρ = 0.19, p = 0.06) and predictive accuracy was modest (AUC 0.584), while LVOT VTI performed best (AUC 0.700). NT-proBNP outperformed all echocardiographic parameters in both groups. Conclusions: The Virtue Index reflects integrated hemodynamics and shows phenotype-dependent prognostic value in AHF, being more informative in HFpEF than in HFrEF. Although NT-proBNP remained superior, Virtue may complement biomarker-based risk assessment by offering a rapid, bedside estimate of short-term mortality risk.


  • Open Access

    VIRTUE: An Innovative Ejection Fraction-Based Index for Predicting Outcomes in Acute Heart Failure

    by Popescu Cristian Dan, Ciobanu Mara, Diana Țînț, Nechita Cristian Alexandru

    Background/Objectives: Acute heart failure (AHF) is a heterogeneous clinical syndrome, and prognosis varies depending on the ejection fraction phenotype. Although the N-terminal pro–B-type natriuretic peptide (NT-proBNP) remains the benchmark biomarker, conventional echocardiographic measures such as the tricuspid annular plane systolic excursion (TAPSE), the right ventricular to right atrial pressure gradient (RV–RA gradient), and the left ventricular outflow tract velocity–time integral (LVOT VTI) provide only partial prognostic information.We previously proposed the Virtue Index, defined as the ratio between the RV–RA gradient and the product of TAPSE and LVOT VTI, reflecting the interaction between right and left ventricular performance. The present study aimed to assess the clinical and prognostic behavior of the index in a cohort of patients with AHF and to determine whether its performance differs between reduced and preserved ejection fraction phenotypes. Methods: We retrospectively analyzed 222 patients admitted with a diagnosis of AHF. Complete echocardiographic data for Virtue Index calculation were available in 168 patients (99 [59%] with heart failure with reduced ejection fraction [HFrEF] and 69 [41%] with heart failure with preserved ejection fraction [HFpEF]). Patients with mid-range ejection fraction (40–49%) or incomplete echocardiographic parameters were excluded from subgroup analyses but retained for descriptive statistics where applicable. Correlation with NT-proBNP was evaluated using Spearman rank testing with bootstrap confidence intervals. Prognostic performance for in-hospital mortality was analyzed using ROC curves, area under the curve (AUC) with bootstrap intervals, and pairwise DeLong comparisons. Results: In the HFpEF subgroup, the index correlated moderately with NT-proBNP (ρ = 0.38, 95% CI 0.13–0.58, p = 0.002) and demonstrated fair prognostic discrimination (AUC 0.704, 95% CI 0.53–0.85), comparable to the RV–RA gradient (AUC 0.724) and higher than TAPSE (AUC 0.637) or LVOT VTI (AUC 0.669). In contrast, in HFrEF, the index showed a weak, non-significant correlation with NT-proBNP (ρ = 0.19, p = 0.06) and modest predictive accuracy (AUC 0.584, 95% CI 0.36–0.79), while LVOT VTI achieved the best discrimination (AUC 0.700). NT-proBNP remained superior in both subgroups (AUC 0.744 in HFrEF, 0.838 in HFpEF). Conclusions: The Virtue Index reflects integrated haemodynamic function and may demonstrate a phenotype-dependent prognostic role in AHF. In our study, its value was more evident in HFpEF, whereas in HFrEF traditional parameters, especially LVOT VTI, remained stronger predictors. Although NT-proBNP consistently outperformed Virtue, the index may complement biomarker assessment by providing rapid, bedside risk stratification of short-term mortality.

  • Open Access

    Linking Heart Function to Prognosis: The Role of a Novel Echocardiographic Index and NT-proBNP in Acute Heart Failure

    by Dan-Cristian Popescu, Mara Ciobanu, Diana Țînț, Alexandru-Cristian Nechita

    Background and Objectives: Risk stratification in acute heart failure (AHF) remains challenging, particularly in settings where biomarker availability is limited. Echocardiography offers valuable hemodynamic insights, but no single parameter fully captures the complexity of biventricular dysfunction and pressure overload. This study aimed to evaluate a novel echocardiographic index (ViRTUE Index–VTI-RVRA-TAPSE Unified Evaluation) integrating a peak systolic gradient between the right ventricle and right atrium (RV-RA gradient), tricuspid annular plane systolic excursion (TAPSE), the velocity–time integral in the left ventricular outflow tract (VTI LVOT), NT-proBNP (N-terminal pro–B-type Natriuretic Peptide) levels, and in-hospital mortality among patients with AHF. Materials and Methods: We retrospectively analyzed 123 patients admitted with AHF. Echocardiographic evaluation at admission included TAPSE, VTI LVOT, and the RV-RA gradient. An index was calculated as RV−RA gradient TAPSE x VTI LVOT. NT-proBNP levels and in-hospital outcomes were recorded. Statistical analysis included correlation, logistic regression, and ROC curve evaluation. Results: The proposed index showed a significant positive correlation with NT-proBNP values (r = 0.543, p < 0.0001) and good discriminative ability for elevated NT-proBNP (AUC = 0.79). It also correlated with in-hospital mortality (r = 0.193, p = 0.032) and showed moderate prognostic performance (AUC = 0.68). Higher index values were associated with greater mortality risk. Conclusions: This novel index, based on standard echocardiographic measurements, reflects both systolic dysfunction and pressure overload in AHF. Its correlation with NT-proBNP and in-hospital mortality highlights its potential as a practical, accessible bedside tool for early risk stratification, particularly when biomarker testing is unavailable or delayed.